

SUPPLEMENTAL MATERIALS

Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis


Andrew Blauvelt¹, Bruce Strober², Gaia Gallo³, Yuxin Ding³, Yun-Fei Chen³, Martin Dossenbach³,
Lidia Rodriguez Calleja⁴, Linda Stein Gold⁵, Jonathan Silverberg⁶

¹Blauvelt Consulting, LLC, Annapolis, USA, ²Yale University School of Medicine, New Haven, and Central Connecticut Dermatology, Cromwell, USA, ³Eli Lilly and Company, Indianapolis, USA, ⁴Almirall, Barcelona, Spain, ⁵Henry Ford Health System, Detroit, USA, ⁶George Washington University School of Medicine and Health Sciences, Washington, DC, USA

This study was funded by Dermira, a wholly owned subsidiary of Eli Lilly and Company.

Almirall, S.A. has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside of Europe.

Study Design: ADvocate1 and ADvocate2



^aUse of topical/systemic treatments for AD prohibited; ^b424 patients (ADvocate1) and 445 patients (ADvocate2) with moderate-to-severe AD originally randomized. Pooled mITT population excluded 18 patients with non-confirmed eligibility in ADvocate 2 (N=851); ^c500 mg LD at Week 0 and Week 2; ^d≤30-day Screening Period; ^eIGA (0,1) with ≥2-point improvement from baseline; ^fFDA primary endpoint; ^gEMA co-primary endpoint.

Note: Figure is not the full study design; only the first 16 weeks of both trials is shown.

AD=atopic dermatitis; EASI=Eczema Area and Severity Index; EASI 75=≥75% improvement from baseline in EASI; EMA=European Medicines Agency; FDA=US Food and Drug Administration; IGA=Investigator's Global Assessment; IGA (0,1)=IGA response of clear or almost clear; IR=inadequate responder; LD=loading dose; LEBRI=lebrikizumab; mITT=modified intent-to-treat; PBO=placebo; Q2W=every 2 weeks.

Baseline Demographics and Disease Characteristics

	Cluster 1A (N=212)	Cluster 1B (N=180)	Cluster 1C (N=85)	Cluster 2 (N=87)
Age, years, mean (SD)	34.3 (16.3)	36.8 (16.9)	36.6 (16.3)	40.3 (20.6)
Female	109 (51.4)	96 (53.3)	34 (40.0)	38 (43.7)
Race				
Asian	39 (18.4)	39 (21.7)	17 (20.0)	22 (25.3)
Black or African American	19 (9.0)	19 (10.6)	11 (12.9)	9 (10.3)
White	144 (67.9)	110 (61.1)	55 (64.7)	55 (63.2)
Other^a	10 (4.7)	12 (6.7)	2 (2.4)	1 (1.1)
Duration since onset of AD, years, mean (SD)	21.9 (13.9)	21.4 (14.8)	20.7 (15.3)	20.8 (17.9)
IGA				
3	130 (61.3)	108 (60.0)	57 (67.1)	50 (57.5)
4	82 (38.7)	72 (40.0)	28 (32.9)	37 (42.5)
EASI, mean (SD)	30.2 (12.4)	29.4 (11.8)	27.6 (9.9)	28.5 (11.0)
Pruritus NRS, mean (SD)	7.2 (1.8)	7.1 (2.0)	7.6 (1.7)	7.1 (2.2)
DLQI, mean (SD)	14.8 (7.4)	15.7 (7.2)	14.7 (6.7)	16.2 (7.0)

^aThe "other" category included American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, and not reported.

Note: Data are n (%) unless stated otherwise.

AD=atopic dermatitis; DLQI=Dermatology Life Quality Index; EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; NRS=Numeric Rating Scale; SD=standard deviation.